title: Sequential bilateral transplantation in Parkinson's disease: effects of the second graft.
abstract: Five parkinsonian patients who had received implants of human embryonic mesencephalic tissue unilaterally in the striatum 10-56 months earlier were grafted with tissue from four to eight donors into the putamen (four patients) or the putamen plus the caudate nucleus (one patient) on the other side, and were followed for 18-24 months. After 12-18 months, PET showed a mean 85% increase in 6-L-[18F]fluorodopa uptake in the putamen with the second graft, whereas there was no significant further change in the previously transplanted putamen. Two patients exhibited marked additional improvements after their second graft: 'on-off' fluctuations virtually disappeared, movement speed increased, and L-dopa could be withdrawn in one patient and reduced by 70% in the other. The improvement in one patient was moderate. Two patients with atypical features, who responded poorly to the first graft, worsened following the second transplantation. These findings indicate that sequential transplantation in patients does not compromise the survival and function of either the first or the second graft. Moreover, putamen grafts that restore fluorodopa uptake to normal levels can give improvements of major therapeutic value.
authors.affiliation: Division of Neurology, Department of Clinical Neuroscience, University of Lund, Sweden.
authors.forename: P
authors.initials: P
authors.lastname: Hagell
authors.forename: A
authors.initials: A
authors.lastname: Schrag
authors.forename: P
authors.initials: P
authors.lastname: Piccini
authors.forename: M
authors.initials: M
authors.lastname: Jahanshahi
authors.forename: R
authors.initials: R
authors.lastname: Brown
authors.forename: S
authors.initials: S
authors.lastname: Rehncrona
authors.forename: H
authors.initials: H
authors.lastname: Widner
authors.forename: P
authors.initials: P
authors.lastname: Brundin
authors.forename: J C
authors.initials: JC
authors.lastname: Rothwell
authors.forename: P
authors.initials: P
authors.lastname: Odin
authors.forename: G K
authors.initials: GK
authors.lastname: Wenning
authors.forename: P
authors.initials: P
authors.lastname: Morrish
authors.forename: B
authors.initials: B
authors.lastname: Gustavii
authors.forename: A
authors.initials: A
authors.lastname: Björklund
authors.forename: D J
authors.initials: DJ
authors.lastname: Brooks
authors.forename: C D
authors.initials: CD
authors.lastname: Marsden
authors.forename: N P
authors.initials: NP
authors.lastname: Quinn
authors.forename: O
authors.initials: O
authors.lastname: Lindvall
mesh_terms: D000328:Adult; D016380:Brain Tissue Transplantation / Q000379:methods / Q000502:physiology; D002421:Caudate Nucleus / Q000601:surgery; D016332:Fetal Tissue Transplantation / Q000379:methods / Q000502:physiology; D005500:Follow-Up Studies; D007839:Functional Laterality; D006085:Graft Survival; D006801:Humans; D008297:Male; D008636:Mesencephalon / Q000637:transplantation*; D008875:Middle Aged; D010300:Parkinson Disease / Q000601:surgery*; D011699:Putamen / Q000601:surgery; D012086:Reoperation; D013997:Time Factors; D016896:Treatment Outcome